Centre for Gene Therapeutics, M.G. DeGroote Institute for Infectious Disease Research, and Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, L8N 3Z5 Canada.
Trends Immunol. 2010 Jul;31(7):247-52. doi: 10.1016/j.it.2010.05.002. Epub 2010 Jun 11.
Protection against pulmonary tuberculosis (TB) by vaccination is often ascribed to the presence of TB-reactive T cells in the lung before infection. Challenging this view, new studies analyzing vaccine-induced T cells in various tissue compartments after parenteral immunization suggest a poor correlation between the presence of anti-TB T cells in the lung interstitium and spleen before Mycobacterium tuberculosis exposure and protection. In contrast, respiratory mucosal immunization leads to distribution of T cells not only in the lung interstitium and spleen, but also in the airway lumen, and the presence of these cells correlates well with protection. Furthermore, airway luminal recruitment of parenteral vaccine-induced T cells in peripheral tissues prior to M. tuberculosis challenge restores protection. We propose that understanding the biology of airway luminal T cells holds important implications for developing effective TB vaccination strategies.
疫苗接种预防肺结核 (TB) 的作用通常归因于感染前肺部存在针对 TB 的 T 细胞。然而,新的研究分析了各种组织隔室中疫苗诱导的 T 细胞,这些研究对这一观点提出了挑战,表明在接触结核分枝杆菌之前,肺部间质和脾脏中抗 TB T 细胞的存在与保护作用之间相关性较差。相比之下,呼吸道黏膜免疫不仅会导致 T 细胞分布在肺部间质和脾脏中,还会分布在气道腔中,并且这些细胞的存在与保护作用密切相关。此外,在结核分枝杆菌挑战之前,外周组织中气道腔募集的疫苗诱导的 T 细胞可恢复保护作用。我们提出,了解气道腔 T 细胞的生物学特性对开发有效的结核病疫苗接种策略具有重要意义。